Professional Documents
Culture Documents
Introduction The role of androgen deprivation therapy (ADT), in nowadays accepted as a first
line treatment of symptomatic metastatic prostate cancer, but for castration‐resistant prostate
cancer (CRPC) is highly controversial. ADT is used treat men with clinically localized prostate
cancer, biochemical recurrence after radical prostatectomy, locally advanced disease, lymph
node metastases, and asymptomatic metastatic disease.
Material and methods In the study were included a total number of 50 patients with castration‐
resistant prostate cancer in 3 groups. I group 24 patients were included with CRPC and bilateral
orchiectomy who received occasional intermittent treatment with ADT +docetaxel+
enzalutamide, II group 24 patients with CRPC without orchiectomy with continue treatment with
GnRH antagonists/LHRH analogues + enzalutamide,
III group 6 patients after RPE, with biochemical recurrence and local recurrence defined by
Response Evaluation Criteria in Solid Tumors (RECIST), treated by ADT + enzalutamide. PSA
total, testosterone, and MRI/ abdominal-pelvic CT scan, and bone scintigraphy was performed
for all patients.
Results PSA response was significantly lower at the patients treated form I and III group with
enzalutamide, with no difference at testosterone level. During the follow up period during 36
month the median follow-up of 26 months, PSA progression was significantly longer in the
group I and II than in the very-low testosterone (P<0.001) in group III.
Conclusions The second-line anti-hormonal therapeutic medication should be included into the
routine control of androgen suppression at the patients with CRPC, significant decrease de
development of new metastasis, and increase the life expectancy for this patients.
Key words: Prostate cancer, PSA, Androgen deprivation therapy